Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Infarction | 226 | 2024 | 11728 | 9.780 |
Why?
|
Acute Coronary Syndrome | 87 | 2023 | 2337 | 9.780 |
Why?
|
Lactones | 23 | 2021 | 329 | 7.340 |
Why?
|
Troponin I | 40 | 2023 | 619 | 6.720 |
Why?
|
Shock, Cardiogenic | 38 | 2024 | 688 | 5.740 |
Why?
|
Coronary Care Units | 20 | 2024 | 214 | 5.260 |
Why?
|
Pyridines | 30 | 2021 | 2822 | 4.900 |
Why?
|
Acetanilides | 21 | 2014 | 168 | 4.550 |
Why?
|
Troponin T | 29 | 2023 | 753 | 4.530 |
Why?
|
Heart Failure | 102 | 2024 | 10905 | 4.420 |
Why?
|
Cardiology | 30 | 2024 | 1668 | 4.370 |
Why?
|
Troponin | 28 | 2023 | 524 | 4.120 |
Why?
|
Angina, Unstable | 43 | 2016 | 926 | 3.940 |
Why?
|
Natriuretic Peptide, Brain | 54 | 2024 | 1573 | 3.940 |
Why?
|
Platelet Aggregation Inhibitors | 40 | 2022 | 3068 | 3.250 |
Why?
|
Receptor, PAR-1 | 11 | 2019 | 113 | 2.980 |
Why?
|
Piperazines | 24 | 2014 | 2491 | 2.880 |
Why?
|
Thrombolytic Therapy | 59 | 2023 | 2161 | 2.680 |
Why?
|
Secondary Prevention | 27 | 2021 | 1531 | 2.400 |
Why?
|
Atherosclerosis | 21 | 2023 | 3444 | 2.370 |
Why?
|
Electrocardiography | 62 | 2022 | 6442 | 2.100 |
Why?
|
Intensive Care Units | 26 | 2024 | 3680 | 2.030 |
Why?
|
Angioplasty, Balloon, Coronary | 25 | 2021 | 1873 | 1.970 |
Why?
|
Risk Assessment | 97 | 2023 | 23337 | 1.950 |
Why?
|
Tetrazoles | 13 | 2024 | 836 | 1.900 |
Why?
|
Myocardial Ischemia | 30 | 2024 | 2148 | 1.890 |
Why?
|
Coronary Disease | 41 | 2014 | 6078 | 1.870 |
Why?
|
Enalapril | 9 | 2024 | 327 | 1.860 |
Why?
|
Stroke | 43 | 2024 | 9981 | 1.850 |
Why?
|
Fibrinolytic Agents | 43 | 2020 | 2158 | 1.840 |
Why?
|
Angiotensin Receptor Antagonists | 12 | 2024 | 924 | 1.840 |
Why?
|
Double-Blind Method | 61 | 2024 | 12035 | 1.760 |
Why?
|
Chest Pain | 12 | 2023 | 1114 | 1.730 |
Why?
|
Extracorporeal Membrane Oxygenation | 11 | 2024 | 1356 | 1.730 |
Why?
|
Enoxaparin | 22 | 2010 | 377 | 1.720 |
Why?
|
Critical Care | 28 | 2024 | 2644 | 1.690 |
Why?
|
Peptide Fragments | 34 | 2024 | 5096 | 1.670 |
Why?
|
Embolism | 6 | 2023 | 409 | 1.650 |
Why?
|
Atrial Fibrillation | 14 | 2024 | 5034 | 1.640 |
Why?
|
Hemorrhage | 31 | 2024 | 3461 | 1.580 |
Why?
|
Peripheral Arterial Disease | 10 | 2021 | 1188 | 1.580 |
Why?
|
Muscle, Smooth, Vascular | 13 | 2021 | 1504 | 1.570 |
Why?
|
Receptors, Thrombin | 5 | 2015 | 131 | 1.570 |
Why?
|
Humans | 534 | 2024 | 744220 | 1.560 |
Why?
|
C-Reactive Protein | 42 | 2023 | 3778 | 1.510 |
Why?
|
Biphenyl Compounds | 13 | 2024 | 914 | 1.490 |
Why?
|
Cardiopulmonary Resuscitation | 3 | 2022 | 978 | 1.480 |
Why?
|
Angina Pectoris | 12 | 2018 | 977 | 1.460 |
Why?
|
Heart-Assist Devices | 12 | 2023 | 1196 | 1.460 |
Why?
|
Pravastatin | 17 | 2016 | 395 | 1.440 |
Why?
|
Enzyme Inhibitors | 16 | 2014 | 3800 | 1.440 |
Why?
|
Heart Injuries | 3 | 2021 | 209 | 1.430 |
Why?
|
Cardiovascular Diseases | 48 | 2024 | 15161 | 1.420 |
Why?
|
Heptanoic Acids | 16 | 2012 | 343 | 1.420 |
Why?
|
Uracil | 4 | 2018 | 165 | 1.370 |
Why?
|
American Heart Association | 20 | 2023 | 1056 | 1.330 |
Why?
|
Aged | 221 | 2024 | 163253 | 1.320 |
Why?
|
Registries | 34 | 2024 | 8090 | 1.290 |
Why?
|
Thrombosis | 11 | 2022 | 2968 | 1.270 |
Why?
|
Middle Aged | 249 | 2024 | 213367 | 1.270 |
Why?
|
Prognosis | 89 | 2024 | 29050 | 1.270 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2022 | 339 | 1.260 |
Why?
|
Anticholesteremic Agents | 9 | 2022 | 979 | 1.240 |
Why?
|
Hospital Mortality | 38 | 2024 | 5316 | 1.240 |
Why?
|
Myocardial Reperfusion | 15 | 2014 | 351 | 1.210 |
Why?
|
Hospitalization | 41 | 2024 | 10262 | 1.190 |
Why?
|
Male | 295 | 2024 | 350027 | 1.170 |
Why?
|
Intra-Aortic Balloon Pumping | 6 | 2024 | 219 | 1.130 |
Why?
|
Female | 298 | 2024 | 380197 | 1.130 |
Why?
|
Shock | 3 | 2023 | 318 | 1.110 |
Why?
|
Treatment Outcome | 116 | 2024 | 63119 | 1.100 |
Why?
|
Growth Differentiation Factor 15 | 7 | 2023 | 176 | 1.100 |
Why?
|
Glycopeptides | 6 | 2016 | 224 | 1.090 |
Why?
|
Hemodynamics | 9 | 2023 | 4199 | 1.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 23 | 2023 | 3256 | 1.060 |
Why?
|
Diabetes Mellitus, Type 2 | 18 | 2023 | 11732 | 1.050 |
Why?
|
Thiazoles | 4 | 2021 | 1484 | 1.050 |
Why?
|
Coronary Artery Disease | 23 | 2023 | 6489 | 1.040 |
Why?
|
Acute Disease | 53 | 2021 | 7148 | 1.040 |
Why?
|
Pyrroles | 16 | 2012 | 1143 | 1.030 |
Why?
|
Stroke Volume | 22 | 2024 | 5008 | 1.020 |
Why?
|
Myocytes, Smooth Muscle | 5 | 2014 | 687 | 1.010 |
Why?
|
Randomized Controlled Trials as Topic | 50 | 2024 | 9960 | 0.990 |
Why?
|
Receptors, Notch | 9 | 2013 | 739 | 0.980 |
Why?
|
Cardiovascular System | 3 | 2023 | 832 | 0.970 |
Why?
|
Critical Illness | 10 | 2023 | 2670 | 0.960 |
Why?
|
Heparin | 21 | 2023 | 1637 | 0.960 |
Why?
|
Risk Factors | 96 | 2024 | 72280 | 0.950 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 18 | 2008 | 641 | 0.920 |
Why?
|
Ventricular Dysfunction, Left | 8 | 2023 | 2072 | 0.920 |
Why?
|
Glucosides | 5 | 2024 | 451 | 0.910 |
Why?
|
Peroxidase | 6 | 2016 | 611 | 0.910 |
Why?
|
Calgranulin A | 3 | 2021 | 79 | 0.900 |
Why?
|
Calgranulin B | 3 | 2021 | 84 | 0.900 |
Why?
|
Patient Admission | 6 | 2020 | 1380 | 0.880 |
Why?
|
Drug Combinations | 14 | 2024 | 1962 | 0.860 |
Why?
|
Coronary Circulation | 17 | 2019 | 1573 | 0.840 |
Why?
|
Piperidines | 4 | 2018 | 1605 | 0.830 |
Why?
|
Creatine Kinase, MB Form | 11 | 2014 | 214 | 0.790 |
Why?
|
Receptors, Cell Surface | 8 | 2013 | 2867 | 0.790 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 13 | 2024 | 1518 | 0.780 |
Why?
|
Galectin 3 | 3 | 2016 | 227 | 0.760 |
Why?
|
Predictive Value of Tests | 44 | 2021 | 15070 | 0.760 |
Why?
|
Recurrence | 34 | 2020 | 8343 | 0.760 |
Why?
|
Heart Diseases | 8 | 2019 | 2790 | 0.750 |
Why?
|
Receptor, Notch1 | 6 | 2010 | 502 | 0.750 |
Why?
|
Hedgehog Proteins | 5 | 2021 | 783 | 0.750 |
Why?
|
Anticoagulants | 19 | 2024 | 4599 | 0.740 |
Why?
|
Vascular Surgical Procedures | 4 | 2020 | 1475 | 0.740 |
Why?
|
Benzhydryl Compounds | 7 | 2024 | 845 | 0.740 |
Why?
|
Myocardium | 11 | 2021 | 4776 | 0.730 |
Why?
|
Tyrosine | 8 | 2008 | 1461 | 0.730 |
Why?
|
Death, Sudden, Cardiac | 10 | 2021 | 1541 | 0.730 |
Why?
|
Blood Chemical Analysis | 2 | 2020 | 440 | 0.720 |
Why?
|
Protein Precursors | 10 | 2016 | 1154 | 0.710 |
Why?
|
CD40 Ligand | 6 | 2021 | 526 | 0.710 |
Why?
|
Cardiovascular Agents | 8 | 2021 | 850 | 0.700 |
Why?
|
Thiophenes | 4 | 2014 | 589 | 0.690 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 697 | 0.670 |
Why?
|
Proteomics | 4 | 2023 | 3637 | 0.670 |
Why?
|
Coronary Artery Bypass | 12 | 2020 | 2289 | 0.670 |
Why?
|
Syndrome | 29 | 2020 | 3250 | 0.660 |
Why?
|
Kaplan-Meier Estimate | 18 | 2019 | 6535 | 0.660 |
Why?
|
Ischemia | 4 | 2021 | 1914 | 0.650 |
Why?
|
Diagnostic Techniques, Cardiovascular | 8 | 2019 | 153 | 0.650 |
Why?
|
Troponin C | 2 | 2016 | 25 | 0.640 |
Why?
|
Collagen Type I | 2 | 2019 | 592 | 0.630 |
Why?
|
Neprilysin | 5 | 2023 | 439 | 0.630 |
Why?
|
Coronary Thrombosis | 6 | 2014 | 494 | 0.630 |
Why?
|
Proportional Hazards Models | 25 | 2022 | 12355 | 0.610 |
Why?
|
Triage | 8 | 2020 | 976 | 0.600 |
Why?
|
Ticlopidine | 9 | 2014 | 899 | 0.590 |
Why?
|
Simvastatin | 5 | 2019 | 360 | 0.590 |
Why?
|
Atrial Natriuretic Factor | 10 | 2016 | 393 | 0.590 |
Why?
|
Myocarditis | 2 | 2023 | 771 | 0.580 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 61 | 0.580 |
Why?
|
Ventricular Function, Left | 10 | 2024 | 3669 | 0.580 |
Why?
|
Cyclopropanes | 2 | 2016 | 416 | 0.580 |
Why?
|
Terminology as Topic | 6 | 2019 | 1548 | 0.580 |
Why?
|
Creatine Kinase | 7 | 2004 | 694 | 0.570 |
Why?
|
Platelet Aggregation | 2 | 2010 | 800 | 0.570 |
Why?
|
Thromboembolism | 2 | 2021 | 985 | 0.560 |
Why?
|
Consensus | 6 | 2021 | 2958 | 0.560 |
Why?
|
Time Factors | 44 | 2021 | 40063 | 0.560 |
Why?
|
Drug Therapy, Combination | 20 | 2019 | 6485 | 0.540 |
Why?
|
Prospective Studies | 38 | 2023 | 53280 | 0.540 |
Why?
|
Heart Arrest | 2 | 2023 | 1470 | 0.540 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2017 | 96 | 0.530 |
Why?
|
Follow-Up Studies | 39 | 2020 | 39045 | 0.530 |
Why?
|
North America | 5 | 2023 | 1250 | 0.520 |
Why?
|
Cholesterol | 5 | 2022 | 2911 | 0.510 |
Why?
|
Algorithms | 12 | 2023 | 13885 | 0.510 |
Why?
|
Pulsatile Flow | 4 | 2013 | 332 | 0.490 |
Why?
|
Standard of Care | 3 | 2017 | 564 | 0.490 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2017 | 293 | 0.490 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2013 | 300 | 0.470 |
Why?
|
Exercise Test | 7 | 2017 | 2075 | 0.470 |
Why?
|
Oxygen | 2 | 2022 | 4187 | 0.470 |
Why?
|
Emergency Service, Hospital | 14 | 2023 | 7659 | 0.470 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2020 | 686 | 0.470 |
Why?
|
Biological Assay | 2 | 2015 | 652 | 0.470 |
Why?
|
Antirheumatic Agents | 1 | 2023 | 1339 | 0.460 |
Why?
|
Guideline Adherence | 3 | 2020 | 2266 | 0.460 |
Why?
|
Signal Transduction | 12 | 2017 | 23404 | 0.460 |
Why?
|
Disease Management | 9 | 2021 | 2458 | 0.460 |
Why?
|
Intracranial Hemorrhages | 9 | 2016 | 855 | 0.450 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 2 | 2016 | 55 | 0.450 |
Why?
|
Neointima | 2 | 2013 | 135 | 0.450 |
Why?
|
Respiratory Insufficiency | 4 | 2021 | 1199 | 0.450 |
Why?
|
Adiponectin | 2 | 2017 | 1100 | 0.450 |
Why?
|
Risk | 19 | 2021 | 9685 | 0.440 |
Why?
|
Antithrombins | 4 | 2008 | 304 | 0.440 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 934 | 0.440 |
Why?
|
Emergency Medical Services | 9 | 2023 | 1916 | 0.430 |
Why?
|
Coronary Angiography | 27 | 2020 | 4578 | 0.430 |
Why?
|
Medical Staff | 1 | 2012 | 43 | 0.430 |
Why?
|
Sensitivity and Specificity | 21 | 2021 | 14726 | 0.430 |
Why?
|
Myocardial Revascularization | 10 | 2021 | 841 | 0.420 |
Why?
|
Pulmonary Embolism | 3 | 2023 | 2375 | 0.420 |
Why?
|
United States | 53 | 2024 | 69867 | 0.410 |
Why?
|
Potassium | 2 | 2016 | 1336 | 0.410 |
Why?
|
Carotid Arteries | 3 | 2014 | 952 | 0.400 |
Why?
|
Arrhythmias, Cardiac | 8 | 2018 | 2267 | 0.400 |
Why?
|
Osteoprotegerin | 1 | 2012 | 176 | 0.390 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 1965 | 0.390 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 229 | 0.390 |
Why?
|
Severity of Illness Index | 24 | 2021 | 15538 | 0.390 |
Why?
|
Survival Analysis | 22 | 2019 | 10250 | 0.390 |
Why?
|
Thoracic Surgical Procedures | 1 | 2015 | 342 | 0.390 |
Why?
|
Diagnostic Imaging | 4 | 2020 | 3508 | 0.380 |
Why?
|
Societies, Medical | 8 | 2021 | 3741 | 0.370 |
Why?
|
Respiration, Artificial | 3 | 2020 | 2569 | 0.370 |
Why?
|
Glomerular Filtration Rate | 9 | 2023 | 2170 | 0.370 |
Why?
|
Death | 7 | 2020 | 678 | 0.370 |
Why?
|
Multimedia | 1 | 2010 | 77 | 0.370 |
Why?
|
Decision Support Techniques | 6 | 2019 | 1955 | 0.360 |
Why?
|
Immunoassay | 8 | 2010 | 752 | 0.360 |
Why?
|
Survival Rate | 21 | 2020 | 12781 | 0.360 |
Why?
|
Peptides | 5 | 2019 | 4407 | 0.360 |
Why?
|
Angiopoietin-1 | 2 | 2007 | 114 | 0.360 |
Why?
|
Research Report | 3 | 2021 | 355 | 0.360 |
Why?
|
Angioplasty, Balloon | 2 | 2012 | 653 | 0.350 |
Why?
|
Renin-Angiotensin System | 4 | 2020 | 759 | 0.350 |
Why?
|
Models, Educational | 1 | 2012 | 377 | 0.350 |
Why?
|
Critical Pathways | 1 | 2013 | 476 | 0.350 |
Why?
|
Isoenzymes | 7 | 2004 | 1726 | 0.350 |
Why?
|
Sodium Channel Blockers | 3 | 2015 | 176 | 0.350 |
Why?
|
Thrombin | 3 | 2021 | 598 | 0.340 |
Why?
|
Endpoint Determination | 5 | 2018 | 601 | 0.340 |
Why?
|
Incidence | 25 | 2023 | 20945 | 0.330 |
Why?
|
Cystatin C | 3 | 2018 | 250 | 0.330 |
Why?
|
Conscious Sedation | 1 | 2013 | 528 | 0.330 |
Why?
|
Analgesia | 1 | 2013 | 462 | 0.330 |
Why?
|
Stents | 7 | 2013 | 3280 | 0.330 |
Why?
|
Cardiac Surgical Procedures | 1 | 2024 | 3533 | 0.330 |
Why?
|
Clinical Trials as Topic | 15 | 2024 | 7908 | 0.330 |
Why?
|
Drug Approval | 1 | 2015 | 741 | 0.320 |
Why?
|
Pericytes | 2 | 2011 | 291 | 0.320 |
Why?
|
Tachycardia, Ventricular | 3 | 2014 | 1273 | 0.320 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 361 | 0.320 |
Why?
|
Coronary Vessels | 7 | 2013 | 3107 | 0.320 |
Why?
|
Drug-Eluting Stents | 1 | 2014 | 753 | 0.310 |
Why?
|
Renal Replacement Therapy | 2 | 2020 | 258 | 0.310 |
Why?
|
Diabetes Mellitus | 7 | 2017 | 5755 | 0.310 |
Why?
|
Science | 1 | 2010 | 241 | 0.310 |
Why?
|
Heart Conduction System | 4 | 2014 | 1047 | 0.310 |
Why?
|
Immunoglobulin J Recombination Signal Sequence-Binding Protein | 5 | 2010 | 121 | 0.300 |
Why?
|
Indoles | 6 | 2019 | 1838 | 0.300 |
Why?
|
Ethanol | 3 | 2011 | 1342 | 0.300 |
Why?
|
Ventricular Function | 3 | 2018 | 416 | 0.300 |
Why?
|
Heart Transplantation | 4 | 2023 | 3123 | 0.300 |
Why?
|
Recombinant Proteins | 11 | 2017 | 6612 | 0.300 |
Why?
|
Fibroblast Growth Factors | 3 | 2019 | 879 | 0.290 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2009 | 3506 | 0.290 |
Why?
|
Cardiology Service, Hospital | 2 | 2020 | 246 | 0.290 |
Why?
|
Internationality | 3 | 2020 | 1003 | 0.280 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 820 | 0.280 |
Why?
|
Oxygen Consumption | 2 | 2019 | 1869 | 0.280 |
Why?
|
Cohort Studies | 26 | 2021 | 40559 | 0.280 |
Why?
|
Inflammation | 15 | 2023 | 10634 | 0.270 |
Why?
|
Iron | 2 | 2022 | 1774 | 0.270 |
Why?
|
Cause of Death | 8 | 2019 | 3584 | 0.270 |
Why?
|
Thromboplastin | 2 | 2023 | 291 | 0.270 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 31 | 0.270 |
Why?
|
Sterol O-Acyltransferase | 2 | 2022 | 27 | 0.270 |
Why?
|
Adamantane | 3 | 2017 | 174 | 0.270 |
Why?
|
Retrospective Studies | 38 | 2024 | 77426 | 0.270 |
Why?
|
Aspirin | 10 | 2020 | 3282 | 0.260 |
Why?
|
Cardiotonic Agents | 3 | 2021 | 535 | 0.260 |
Why?
|
Coronary Restenosis | 4 | 2021 | 424 | 0.250 |
Why?
|
Healthcare Disparities | 2 | 2019 | 3158 | 0.250 |
Why?
|
Coronary Stenosis | 2 | 2010 | 834 | 0.250 |
Why?
|
Antifibrinolytic Agents | 2 | 2023 | 254 | 0.250 |
Why?
|
Positive-Pressure Respiration | 2 | 2019 | 632 | 0.250 |
Why?
|
Dipeptides | 3 | 2017 | 409 | 0.250 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 1537 | 0.250 |
Why?
|
Evidence-Based Medicine | 10 | 2020 | 3611 | 0.250 |
Why?
|
Necrosis | 5 | 2013 | 1643 | 0.250 |
Why?
|
Aged, 80 and over | 24 | 2023 | 57768 | 0.250 |
Why?
|
Cardiac Care Facilities | 3 | 2020 | 35 | 0.250 |
Why?
|
Proto-Oncogene Proteins | 3 | 2007 | 4553 | 0.240 |
Why?
|
Consensus Development Conferences as Topic | 2 | 2019 | 170 | 0.240 |
Why?
|
Natriuretic Agents | 2 | 2004 | 25 | 0.240 |
Why?
|
Tissue Plasminogen Activator | 7 | 2009 | 1261 | 0.240 |
Why?
|
Pulmonary Edema | 1 | 2007 | 414 | 0.240 |
Why?
|
Endovascular Procedures | 2 | 2020 | 1979 | 0.240 |
Why?
|
Diabetes Complications | 2 | 2009 | 1361 | 0.230 |
Why?
|
Zygote | 1 | 2024 | 116 | 0.230 |
Why?
|
Practice Guidelines as Topic | 10 | 2021 | 7281 | 0.220 |
Why?
|
Placebos | 5 | 2019 | 1677 | 0.220 |
Why?
|
Civil Defense | 2 | 2022 | 109 | 0.220 |
Why?
|
Brain Ischemia | 2 | 2014 | 3265 | 0.220 |
Why?
|
Genomics | 2 | 2017 | 5722 | 0.220 |
Why?
|
Diagnosis, Differential | 7 | 2019 | 12961 | 0.220 |
Why?
|
Reference Values | 8 | 2011 | 4982 | 0.220 |
Why?
|
Adult | 50 | 2023 | 214035 | 0.220 |
Why?
|
Vascular Patency | 6 | 2016 | 886 | 0.220 |
Why?
|
Lactates | 1 | 2023 | 432 | 0.220 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2023 | 1344 | 0.220 |
Why?
|
Phospholipases A2, Secretory | 2 | 2013 | 31 | 0.220 |
Why?
|
Neovascularization, Physiologic | 2 | 2007 | 1351 | 0.220 |
Why?
|
Vasodilation | 1 | 2007 | 944 | 0.210 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2016 | 361 | 0.210 |
Why?
|
Comorbidity | 11 | 2020 | 10387 | 0.210 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2023 | 2208 | 0.210 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1238 | 0.210 |
Why?
|
Pneumonia, Viral | 4 | 2021 | 3239 | 0.210 |
Why?
|
Heart Valves | 1 | 2024 | 291 | 0.210 |
Why?
|
ROC Curve | 5 | 2014 | 3527 | 0.210 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 45 | 0.210 |
Why?
|
Creatinine | 6 | 2018 | 1919 | 0.210 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 297 | 0.210 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5529 | 0.210 |
Why?
|
Cytokines | 3 | 2023 | 7326 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 11 | 2021 | 10949 | 0.200 |
Why?
|
Research Design | 12 | 2023 | 5987 | 0.200 |
Why?
|
Warfarin | 4 | 2024 | 1496 | 0.200 |
Why?
|
Clinical Laboratory Techniques | 1 | 2007 | 738 | 0.200 |
Why?
|
Cardiac Output, Low | 4 | 2018 | 193 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2023 | 426 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.190 |
Why?
|
Blood Platelets | 1 | 2011 | 2508 | 0.190 |
Why?
|
Transcription Factors | 4 | 2024 | 12207 | 0.190 |
Why?
|
Hospital Rapid Response Team | 1 | 2021 | 57 | 0.190 |
Why?
|
Endothelium, Vascular | 3 | 2011 | 4455 | 0.190 |
Why?
|
Career Choice | 2 | 2019 | 744 | 0.190 |
Why?
|
Vascular Resistance | 1 | 2023 | 937 | 0.190 |
Why?
|
Decision Making | 3 | 2012 | 3888 | 0.190 |
Why?
|
Blood Glucose | 4 | 2010 | 6259 | 0.190 |
Why?
|
Cholesterol, LDL | 7 | 2017 | 2355 | 0.180 |
Why?
|
Cell Proliferation | 4 | 2011 | 10480 | 0.180 |
Why?
|
Multivariate Analysis | 16 | 2014 | 12244 | 0.180 |
Why?
|
Benchmarking | 1 | 2007 | 1042 | 0.180 |
Why?
|
Blood Coagulation Disorders | 1 | 2023 | 337 | 0.180 |
Why?
|
Confidence Intervals | 6 | 2010 | 2970 | 0.180 |
Why?
|
Renal Insufficiency | 4 | 2021 | 804 | 0.180 |
Why?
|
Thrombectomy | 2 | 2023 | 679 | 0.180 |
Why?
|
Myoglobin | 5 | 2003 | 160 | 0.180 |
Why?
|
Serum Amyloid A Protein | 1 | 2000 | 121 | 0.180 |
Why?
|
Patient Advocacy | 1 | 2022 | 353 | 0.180 |
Why?
|
International Cooperation | 4 | 2022 | 1421 | 0.180 |
Why?
|
Assisted Circulation | 1 | 2019 | 104 | 0.180 |
Why?
|
Hypotension | 2 | 2023 | 880 | 0.180 |
Why?
|
Chemokine CCL2 | 4 | 2007 | 617 | 0.180 |
Why?
|
Neopterin | 2 | 2011 | 56 | 0.170 |
Why?
|
RNA, Messenger | 7 | 2013 | 13036 | 0.170 |
Why?
|
Carbon Dioxide | 1 | 2024 | 1147 | 0.170 |
Why?
|
Infarction | 1 | 2021 | 246 | 0.170 |
Why?
|
Receptors, CCR5 | 1 | 2021 | 497 | 0.170 |
Why?
|
Kidney Diseases | 6 | 2019 | 2147 | 0.170 |
Why?
|
Methylamines | 1 | 2020 | 123 | 0.170 |
Why?
|
Half-Life | 3 | 2018 | 659 | 0.170 |
Why?
|
Patient Discharge | 6 | 2020 | 3313 | 0.170 |
Why?
|
Optics and Photonics | 1 | 2021 | 321 | 0.170 |
Why?
|
Extremities | 2 | 2016 | 865 | 0.170 |
Why?
|
Coma | 1 | 2022 | 475 | 0.170 |
Why?
|
Tachycardia | 2 | 2007 | 620 | 0.170 |
Why?
|
Clinical Competence | 4 | 2020 | 4687 | 0.160 |
Why?
|
Disease Progression | 6 | 2023 | 13280 | 0.160 |
Why?
|
Advisory Committees | 2 | 2020 | 774 | 0.160 |
Why?
|
P-Selectin | 1 | 2021 | 600 | 0.160 |
Why?
|
Stress, Mechanical | 5 | 2008 | 1686 | 0.160 |
Why?
|
Cyclic GMP | 1 | 2019 | 409 | 0.160 |
Why?
|
Hypoglycemic Agents | 5 | 2017 | 2875 | 0.160 |
Why?
|
Venous Thromboembolism | 2 | 2023 | 1670 | 0.160 |
Why?
|
Endothelial Cells | 3 | 2011 | 3478 | 0.160 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.160 |
Why?
|
Personnel Administration, Hospital | 1 | 2017 | 8 | 0.160 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 24 | 0.160 |
Why?
|
Diabetic Foot | 2 | 2013 | 355 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3132 | 0.150 |
Why?
|
Symporters | 1 | 2020 | 363 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 497 | 0.150 |
Why?
|
Factor Xa | 1 | 2018 | 162 | 0.150 |
Why?
|
Apolipoproteins | 1 | 2000 | 316 | 0.150 |
Why?
|
Limit of Detection | 2 | 2020 | 265 | 0.150 |
Why?
|
Odds Ratio | 15 | 2016 | 9849 | 0.150 |
Why?
|
Glucuronidase | 1 | 2019 | 207 | 0.150 |
Why?
|
Acute Kidney Injury | 2 | 2020 | 1971 | 0.150 |
Why?
|
Surgical Mesh | 1 | 2020 | 276 | 0.150 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 1 | 2021 | 570 | 0.150 |
Why?
|
Hernia, Ventral | 1 | 2020 | 177 | 0.150 |
Why?
|
Drug Administration Schedule | 6 | 2018 | 4929 | 0.150 |
Why?
|
Chemistry, Clinical | 2 | 2015 | 64 | 0.150 |
Why?
|
Alanine | 6 | 2020 | 572 | 0.150 |
Why?
|
Biomedical Research | 4 | 2023 | 3311 | 0.140 |
Why?
|
Plasminogen Activators | 4 | 2009 | 209 | 0.140 |
Why?
|
Organizational Innovation | 1 | 2020 | 559 | 0.140 |
Why?
|
Electric Countershock | 1 | 2000 | 534 | 0.140 |
Why?
|
Germany | 1 | 2019 | 862 | 0.140 |
Why?
|
Point-of-Care Systems | 3 | 2001 | 1176 | 0.140 |
Why?
|
Phenotype | 6 | 2010 | 16365 | 0.140 |
Why?
|
Fibrin | 2 | 2009 | 506 | 0.140 |
Why?
|
Apolipoproteins E | 4 | 2012 | 1438 | 0.140 |
Why?
|
Ventricular Function, Right | 2 | 2012 | 592 | 0.140 |
Why?
|
Pilot Projects | 5 | 2011 | 8321 | 0.140 |
Why?
|
Sex Characteristics | 3 | 2019 | 2586 | 0.140 |
Why?
|
Terminal Care | 2 | 2022 | 1694 | 0.140 |
Why?
|
Nuclear Proteins | 3 | 2005 | 5853 | 0.130 |
Why?
|
Education, Medical, Graduate | 2 | 2019 | 2291 | 0.130 |
Why?
|
Internship, Nonmedical | 1 | 1995 | 7 | 0.130 |
Why?
|
Nitrates | 1 | 2017 | 265 | 0.130 |
Why?
|
Hyperglycemia | 3 | 2010 | 1372 | 0.130 |
Why?
|
Multicenter Studies as Topic | 7 | 2024 | 1677 | 0.130 |
Why?
|
Certification | 1 | 2019 | 424 | 0.130 |
Why?
|
Natriuretic Peptides | 2 | 2008 | 150 | 0.130 |
Why?
|
Administration, Oral | 6 | 2024 | 3913 | 0.130 |
Why?
|
Platelet Activation | 3 | 2009 | 673 | 0.130 |
Why?
|
Mortality | 5 | 2020 | 2864 | 0.130 |
Why?
|
Transfection | 3 | 2010 | 5892 | 0.130 |
Why?
|
RNA, Small Interfering | 3 | 2013 | 3505 | 0.130 |
Why?
|
Antigens, Bacterial | 1 | 2021 | 1171 | 0.130 |
Why?
|
Cells, Cultured | 6 | 2013 | 19227 | 0.130 |
Why?
|
Reproducibility of Results | 12 | 2021 | 19907 | 0.130 |
Why?
|
Quality Improvement | 3 | 2020 | 3746 | 0.130 |
Why?
|
Prevalence | 6 | 2019 | 15226 | 0.130 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2023 | 1534 | 0.130 |
Why?
|
Psychology, Clinical | 1 | 1995 | 42 | 0.130 |
Why?
|
Communicable Disease Control | 1 | 2022 | 857 | 0.130 |
Why?
|
Renal Dialysis | 2 | 2021 | 1787 | 0.130 |
Why?
|
Case-Control Studies | 11 | 2020 | 21752 | 0.130 |
Why?
|
Sex Factors | 7 | 2022 | 10396 | 0.130 |
Why?
|
Apoptosis | 5 | 2011 | 9728 | 0.120 |
Why?
|
HIV Antibodies | 1 | 2021 | 1322 | 0.120 |
Why?
|
Primary Prevention | 2 | 2012 | 1167 | 0.120 |
Why?
|
Inservice Training | 1 | 2017 | 392 | 0.120 |
Why?
|
Pulmonary Artery | 1 | 2023 | 1912 | 0.120 |
Why?
|
Carotid Artery Diseases | 2 | 2011 | 882 | 0.120 |
Why?
|
Education, Graduate | 1 | 1995 | 81 | 0.120 |
Why?
|
Electrocardiography, Ambulatory | 4 | 2011 | 585 | 0.120 |
Why?
|
Canada | 5 | 2020 | 2065 | 0.120 |
Why?
|
Benzaldehydes | 3 | 2018 | 58 | 0.120 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2014 | 69 | 0.120 |
Why?
|
Patient Selection | 7 | 2019 | 4216 | 0.120 |
Why?
|
Microcirculation | 2 | 2017 | 1286 | 0.120 |
Why?
|
Limb Salvage | 1 | 2016 | 433 | 0.120 |
Why?
|
Reference Standards | 4 | 2019 | 1025 | 0.120 |
Why?
|
Prosthesis-Related Infections | 1 | 2020 | 538 | 0.120 |
Why?
|
Adenosine | 2 | 2016 | 825 | 0.120 |
Why?
|
Recovery of Function | 3 | 2019 | 2925 | 0.120 |
Why?
|
Phosphorylcholine | 1 | 2014 | 162 | 0.120 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2017 | 501 | 0.110 |
Why?
|
Fumarates | 2 | 2013 | 132 | 0.110 |
Why?
|
Rats | 7 | 2014 | 24273 | 0.110 |
Why?
|
DNA-Binding Proteins | 3 | 2005 | 9647 | 0.110 |
Why?
|
Gene Expression Regulation | 6 | 2013 | 12075 | 0.110 |
Why?
|
Multipotent Stem Cells | 1 | 2014 | 186 | 0.110 |
Why?
|
Plaque, Atherosclerotic | 2 | 2017 | 1519 | 0.110 |
Why?
|
Placebo Effect | 2 | 2014 | 502 | 0.110 |
Why?
|
United States Food and Drug Administration | 3 | 2018 | 1583 | 0.110 |
Why?
|
Health Care Costs | 3 | 2019 | 3209 | 0.110 |
Why?
|
Lecithins | 2 | 2022 | 16 | 0.110 |
Why?
|
Professional Practice | 1 | 1995 | 326 | 0.110 |
Why?
|
Temporomandibular Joint Disorders | 1 | 1996 | 215 | 0.110 |
Why?
|
Outpatients | 1 | 2020 | 1486 | 0.110 |
Why?
|
Carotid Artery Injuries | 1 | 2013 | 96 | 0.110 |
Why?
|
Career Mobility | 1 | 1995 | 262 | 0.110 |
Why?
|
Lipoproteins, LDL | 2 | 2006 | 639 | 0.110 |
Why?
|
Pyrrolidines | 5 | 2007 | 342 | 0.110 |
Why?
|
Blood Coagulation | 3 | 2009 | 1127 | 0.110 |
Why?
|
Data Interpretation, Statistical | 3 | 2008 | 2715 | 0.110 |
Why?
|
Postoperative Hemorrhage | 2 | 2006 | 412 | 0.110 |
Why?
|
Ankle Brachial Index | 1 | 2013 | 154 | 0.110 |
Why?
|
Hirudins | 3 | 2008 | 183 | 0.110 |
Why?
|
Arteries | 1 | 2017 | 1119 | 0.110 |
Why?
|
Oximes | 3 | 2018 | 311 | 0.110 |
Why?
|
Orthodontic Appliances | 1 | 1992 | 44 | 0.110 |
Why?
|
Valine | 2 | 2013 | 413 | 0.110 |
Why?
|
Family | 1 | 2023 | 3148 | 0.110 |
Why?
|
Inflammation Mediators | 2 | 2017 | 1889 | 0.110 |
Why?
|
Streptokinase | 2 | 2009 | 188 | 0.100 |
Why?
|
Antibodies, Monoclonal | 5 | 2005 | 9275 | 0.100 |
Why?
|
Quality of Life | 5 | 2020 | 12805 | 0.100 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 897 | 0.100 |
Why?
|
Lipids | 1 | 2023 | 3305 | 0.100 |
Why?
|
Retreatment | 2 | 2012 | 610 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 3871 | 0.100 |
Why?
|
Medication Therapy Management | 4 | 2012 | 127 | 0.100 |
Why?
|
Up-Regulation | 3 | 2020 | 4217 | 0.100 |
Why?
|
Genetic Loci | 2 | 2012 | 2575 | 0.100 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 676 | 0.100 |
Why?
|
Joint Diseases | 1 | 1996 | 480 | 0.100 |
Why?
|
Angiotensins | 2 | 2023 | 151 | 0.100 |
Why?
|
Gingivitis | 1 | 1992 | 124 | 0.100 |
Why?
|
Inpatients | 2 | 2020 | 2518 | 0.100 |
Why?
|
Clinical Protocols | 6 | 2013 | 1462 | 0.100 |
Why?
|
Amides | 2 | 2013 | 459 | 0.100 |
Why?
|
Catalysis | 1 | 2013 | 761 | 0.100 |
Why?
|
Massachusetts | 2 | 2014 | 8663 | 0.100 |
Why?
|
Kidney Failure, Chronic | 3 | 2021 | 2538 | 0.100 |
Why?
|
Cellulitis | 1 | 2013 | 206 | 0.100 |
Why?
|
Carrier Proteins | 2 | 2021 | 5021 | 0.100 |
Why?
|
Hemoglobins | 2 | 2009 | 1533 | 0.100 |
Why?
|
Blood Pressure | 3 | 2022 | 8551 | 0.100 |
Why?
|
Aortic Coarctation | 1 | 2013 | 281 | 0.100 |
Why?
|
Probability | 3 | 2019 | 2505 | 0.100 |
Why?
|
Databases, Factual | 3 | 2020 | 7730 | 0.100 |
Why?
|
Survivors | 1 | 2021 | 2291 | 0.100 |
Why?
|
Amputation Stumps | 1 | 2010 | 39 | 0.100 |
Why?
|
Norway | 1 | 2012 | 448 | 0.100 |
Why?
|
Animals | 21 | 2021 | 168788 | 0.100 |
Why?
|
Kidney | 3 | 2023 | 7183 | 0.100 |
Why?
|
Intestines | 1 | 2020 | 1924 | 0.090 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.090 |
Why?
|
Chlorhexidine | 1 | 1992 | 162 | 0.090 |
Why?
|
Morpholines | 1 | 2014 | 573 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2242 | 0.090 |
Why?
|
Self Administration | 1 | 1991 | 386 | 0.090 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 159 | 0.090 |
Why?
|
Pandemics | 5 | 2023 | 8387 | 0.090 |
Why?
|
Patient Education as Topic | 2 | 2009 | 2277 | 0.090 |
Why?
|
Age Factors | 9 | 2022 | 18367 | 0.090 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2007 | 127 | 0.090 |
Why?
|
RNA Interference | 2 | 2010 | 2890 | 0.090 |
Why?
|
Hyperplasia | 1 | 2013 | 1184 | 0.090 |
Why?
|
Hospitals | 2 | 2022 | 3952 | 0.090 |
Why?
|
Ferritins | 2 | 2023 | 590 | 0.090 |
Why?
|
Heart | 2 | 2023 | 4465 | 0.090 |
Why?
|
Task Performance and Analysis | 2 | 1994 | 780 | 0.090 |
Why?
|
Length of Stay | 2 | 2013 | 6308 | 0.090 |
Why?
|
Health Status | 3 | 2019 | 4034 | 0.090 |
Why?
|
Texas | 5 | 2010 | 392 | 0.090 |
Why?
|
Lipoprotein(a) | 1 | 2013 | 435 | 0.090 |
Why?
|
Exercise Tolerance | 2 | 2017 | 770 | 0.090 |
Why?
|
Specialization | 3 | 2020 | 777 | 0.090 |
Why?
|
Ventricular Premature Complexes | 1 | 2010 | 111 | 0.090 |
Why?
|
Glucose | 2 | 2020 | 4396 | 0.080 |
Why?
|
Education | 1 | 2012 | 543 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2017 | 3201 | 0.080 |
Why?
|
Bacteria | 1 | 2020 | 2114 | 0.080 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2011 | 430 | 0.080 |
Why?
|
Aircraft | 1 | 1990 | 123 | 0.080 |
Why?
|
Immunoglobulin M | 1 | 2014 | 1538 | 0.080 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2011 | 232 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2020 | 1797 | 0.080 |
Why?
|
Combined Modality Therapy | 4 | 2009 | 8628 | 0.080 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4385 | 0.080 |
Why?
|
Negative-Pressure Wound Therapy | 1 | 2010 | 150 | 0.080 |
Why?
|
Immunoglobulin Fab Fragments | 4 | 2004 | 482 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3023 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3340 | 0.080 |
Why?
|
Women's Health | 1 | 2018 | 2034 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2903 | 0.080 |
Why?
|
Hypertension | 2 | 2022 | 8480 | 0.080 |
Why?
|
Promoter Regions, Genetic | 3 | 2010 | 5867 | 0.080 |
Why?
|
Calcium-Binding Proteins | 1 | 2013 | 1080 | 0.080 |
Why?
|
DNA | 2 | 2013 | 7303 | 0.080 |
Why?
|
Aldosterone | 1 | 2013 | 877 | 0.080 |
Why?
|
Lipoproteins, HDL | 2 | 2022 | 638 | 0.080 |
Why?
|
Opportunistic Infections | 1 | 2011 | 389 | 0.080 |
Why?
|
Cell Differentiation | 1 | 2005 | 11478 | 0.080 |
Why?
|
Mendelian Randomization Analysis | 1 | 2013 | 967 | 0.080 |
Why?
|
Alcohol Drinking | 2 | 2011 | 3966 | 0.080 |
Why?
|
Receptor, TIE-1 | 1 | 2007 | 12 | 0.080 |
Why?
|
Microfilament Proteins | 1 | 2013 | 1152 | 0.080 |
Why?
|
Takotsubo Cardiomyopathy | 2 | 2020 | 125 | 0.080 |
Why?
|
Apolipoprotein A-I | 1 | 2009 | 281 | 0.080 |
Why?
|
Waist Circumference | 1 | 2011 | 917 | 0.080 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 2187 | 0.070 |
Why?
|
Body Mass Index | 4 | 2024 | 12718 | 0.070 |
Why?
|
Government Regulation | 1 | 2011 | 522 | 0.070 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 733 | 0.070 |
Why?
|
Apolipoproteins B | 1 | 2009 | 374 | 0.070 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 453 | 0.070 |
Why?
|
Counseling | 1 | 1995 | 1523 | 0.070 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2005 | 339 | 0.070 |
Why?
|
Endothelin-1 | 2 | 2023 | 314 | 0.070 |
Why?
|
Cell Division | 2 | 2024 | 4567 | 0.070 |
Why?
|
Myocytes, Cardiac | 2 | 2013 | 1637 | 0.070 |
Why?
|
Sentinel Surveillance | 1 | 2008 | 281 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1411 | 0.070 |
Why?
|
Anthropometry | 1 | 2011 | 1350 | 0.070 |
Why?
|
Receptor, TIE-2 | 1 | 2007 | 178 | 0.070 |
Why?
|
Ambulatory Care Facilities | 1 | 2013 | 933 | 0.070 |
Why?
|
India | 1 | 2013 | 2199 | 0.070 |
Why?
|
Injections, Intramuscular | 2 | 2021 | 548 | 0.070 |
Why?
|
Bone Marrow Cells | 1 | 2014 | 2513 | 0.070 |
Why?
|
Ventricular Pressure | 1 | 2007 | 199 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2008 | 441 | 0.070 |
Why?
|
History, 21st Century | 1 | 2012 | 1534 | 0.070 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2007 | 264 | 0.070 |
Why?
|
Cell Line | 3 | 2014 | 15999 | 0.070 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 1150 | 0.070 |
Why?
|
Drug Industry | 1 | 2011 | 745 | 0.070 |
Why?
|
Phospholipases A | 1 | 2006 | 216 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 2008 | 0.060 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2078 | 0.060 |
Why?
|
Acute-Phase Proteins | 1 | 2006 | 262 | 0.060 |
Why?
|
Sex Distribution | 1 | 2010 | 2297 | 0.060 |
Why?
|
Photons | 1 | 2008 | 588 | 0.060 |
Why?
|
von Willebrand Factor | 2 | 2007 | 669 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1114 | 0.060 |
Why?
|
Young Adult | 7 | 2021 | 56436 | 0.060 |
Why?
|
Metabolism | 1 | 2005 | 193 | 0.060 |
Why?
|
History, 20th Century | 1 | 2012 | 2739 | 0.060 |
Why?
|
Body Height | 1 | 2010 | 1576 | 0.060 |
Why?
|
Adrenomedullin | 2 | 2016 | 87 | 0.060 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 469 | 0.060 |
Why?
|
Emergencies | 2 | 2019 | 1170 | 0.060 |
Why?
|
Fluoroquinolones | 4 | 2007 | 310 | 0.060 |
Why?
|
Models, Animal | 2 | 2011 | 2171 | 0.060 |
Why?
|
bcl-2-Associated X Protein | 1 | 2005 | 295 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2009 | 720 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2014 | 13990 | 0.060 |
Why?
|
Aromatase | 1 | 2004 | 146 | 0.060 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2006 | 504 | 0.060 |
Why?
|
Matrix Metalloproteinases | 1 | 2006 | 391 | 0.060 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 85 | 0.060 |
Why?
|
Iceland | 1 | 2023 | 183 | 0.060 |
Why?
|
bcl-X Protein | 1 | 2005 | 411 | 0.060 |
Why?
|
Osteoarthritis | 1 | 2011 | 1036 | 0.060 |
Why?
|
Neutrophils | 2 | 2023 | 3717 | 0.060 |
Why?
|
Anti-Infective Agents | 2 | 2007 | 972 | 0.060 |
Why?
|
Leukocyte Count | 2 | 2008 | 1584 | 0.060 |
Why?
|
RNA | 1 | 2013 | 2749 | 0.060 |
Why?
|
Cobalt | 1 | 2003 | 158 | 0.050 |
Why?
|
Down-Regulation | 2 | 2013 | 3001 | 0.050 |
Why?
|
Receptors, Immunologic | 1 | 2009 | 1423 | 0.050 |
Why?
|
Safety Management | 1 | 2008 | 782 | 0.050 |
Why?
|
Adenosine Monophosphate | 2 | 2020 | 275 | 0.050 |
Why?
|
Gene Duplication | 1 | 2004 | 330 | 0.050 |
Why?
|
Linear Models | 1 | 2013 | 5953 | 0.050 |
Why?
|
Injections, Intravenous | 1 | 2005 | 1420 | 0.050 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2006 | 1155 | 0.050 |
Why?
|
Congresses as Topic | 2 | 2018 | 764 | 0.050 |
Why?
|
Receptors, Erythropoietin | 1 | 2022 | 147 | 0.050 |
Why?
|
Chronic Disease | 3 | 2021 | 9147 | 0.050 |
Why?
|
Natriuresis | 1 | 2002 | 124 | 0.050 |
Why?
|
Monocytes | 2 | 2012 | 2594 | 0.050 |
Why?
|
Ventral Thalamic Nuclei | 1 | 2001 | 41 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
Mice | 8 | 2017 | 81178 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2018 | 6367 | 0.050 |
Why?
|
Nerve Tissue Proteins | 3 | 2004 | 4465 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2022 | 216 | 0.050 |
Why?
|
Device Removal | 2 | 2020 | 656 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2011 | 1540 | 0.050 |
Why?
|
Reperfusion Injury | 1 | 2008 | 1026 | 0.050 |
Why?
|
Microscopy, Fluorescence | 1 | 2008 | 2700 | 0.050 |
Why?
|
Research | 2 | 2023 | 1999 | 0.050 |
Why?
|
Europe | 3 | 2018 | 3339 | 0.050 |
Why?
|
Infant | 2 | 2021 | 35129 | 0.050 |
Why?
|
Patient Compliance | 1 | 1991 | 2684 | 0.050 |
Why?
|
Drug Delivery Systems | 2 | 2018 | 2218 | 0.050 |
Why?
|
Myelin P2 Protein | 1 | 2000 | 20 | 0.050 |
Why?
|
Therapeutic Equipoise | 1 | 2020 | 28 | 0.050 |
Why?
|
Ceramides | 1 | 2022 | 199 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2279 | 0.050 |
Why?
|
Statistics as Topic | 5 | 2005 | 2374 | 0.050 |
Why?
|
Tremor | 1 | 2001 | 175 | 0.050 |
Why?
|
Receptors, Transferrin | 1 | 2022 | 296 | 0.050 |
Why?
|
Calibration | 2 | 2017 | 816 | 0.050 |
Why?
|
Sodium | 2 | 2020 | 1623 | 0.050 |
Why?
|
Adolescent | 9 | 2023 | 85759 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2020 | 67 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2020 | 142 | 0.050 |
Why?
|
Hemofiltration | 1 | 2020 | 57 | 0.050 |
Why?
|
Retina | 1 | 2011 | 2616 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2021 | 221 | 0.050 |
Why?
|
England | 1 | 2021 | 523 | 0.050 |
Why?
|
Polypropylenes | 1 | 2020 | 64 | 0.040 |
Why?
|
Mice, Inbred C57BL | 3 | 2017 | 21824 | 0.040 |
Why?
|
Catheters | 1 | 2023 | 425 | 0.040 |
Why?
|
Protein Binding | 2 | 2021 | 9392 | 0.040 |
Why?
|
Vital Signs | 1 | 2021 | 141 | 0.040 |
Why?
|
Serum Albumin | 1 | 2003 | 676 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2021 | 270 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2007 | 1175 | 0.040 |
Why?
|
Wound Healing | 1 | 2010 | 2785 | 0.040 |
Why?
|
Takayasu Arteritis | 1 | 2000 | 96 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
Eicosapentaenoic Acid | 1 | 2023 | 582 | 0.040 |
Why?
|
Actins | 2 | 2005 | 2121 | 0.040 |
Why?
|
Primates | 1 | 2021 | 544 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 3461 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 5396 | 0.040 |
Why?
|
Treatment Failure | 3 | 2016 | 2619 | 0.040 |
Why?
|
Physical Chromosome Mapping | 1 | 1999 | 183 | 0.040 |
Why?
|
Hyperkalemia | 1 | 2021 | 218 | 0.040 |
Why?
|
Communication Barriers | 1 | 2022 | 398 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 280 | 0.040 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1999 | 230 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 4328 | 0.040 |
Why?
|
Computer Security | 1 | 2020 | 263 | 0.040 |
Why?
|
Phospholipids | 1 | 2022 | 781 | 0.040 |
Why?
|
Epidemiologic Methods | 3 | 2008 | 1365 | 0.040 |
Why?
|
Polyesters | 1 | 2020 | 363 | 0.040 |
Why?
|
Hypercholesterolemia | 1 | 2005 | 1151 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2020 | 438 | 0.040 |
Why?
|
Cattle | 3 | 2011 | 3922 | 0.040 |
Why?
|
Disease-Free Survival | 4 | 2017 | 6893 | 0.040 |
Why?
|
Public Health | 2 | 2022 | 2603 | 0.040 |
Why?
|
Device Approval | 1 | 2019 | 163 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1434 | 0.040 |
Why?
|
Aneurysm, False | 1 | 2000 | 276 | 0.040 |
Why?
|
Nanoparticles | 1 | 2009 | 1905 | 0.040 |
Why?
|
Cholesterol, HDL | 3 | 2011 | 1814 | 0.040 |
Why?
|
Ventilator Weaning | 1 | 2018 | 148 | 0.040 |
Why?
|
Echocardiography | 3 | 2017 | 5103 | 0.040 |
Why?
|
Logistic Models | 5 | 2020 | 13409 | 0.040 |
Why?
|
Heart Rate | 3 | 2017 | 4092 | 0.040 |
Why?
|
Medication Adherence | 1 | 2009 | 2062 | 0.040 |
Why?
|
Membrane Proteins | 2 | 2004 | 7879 | 0.040 |
Why?
|
Angiography | 1 | 2022 | 1638 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2012 | 4371 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2023 | 950 | 0.040 |
Why?
|
Plasma | 1 | 2020 | 575 | 0.040 |
Why?
|
Docosahexaenoic Acids | 1 | 2023 | 875 | 0.040 |
Why?
|
Phospholipases A2 | 2 | 2007 | 203 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 2017 | 264 | 0.030 |
Why?
|
Regression Analysis | 3 | 2001 | 6461 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2011 | 3336 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.030 |
Why?
|
Models, Statistical | 2 | 2001 | 5102 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2005 | 3772 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 501 | 0.030 |
Why?
|
Uric Acid | 1 | 2022 | 765 | 0.030 |
Why?
|
Cardiac Output | 1 | 2018 | 854 | 0.030 |
Why?
|
Aortic Aneurysm | 1 | 2000 | 643 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 840 | 0.030 |
Why?
|
Communication | 1 | 1990 | 3749 | 0.030 |
Why?
|
Public Policy | 2 | 2012 | 572 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 383 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2559 | 0.030 |
Why?
|
Hospital Units | 1 | 2016 | 141 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 3712 | 0.030 |
Why?
|
Genome | 1 | 2024 | 1808 | 0.030 |
Why?
|
Respiratory Rate | 1 | 2016 | 162 | 0.030 |
Why?
|
Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2011 | 18027 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2021 | 956 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2006 | 3085 | 0.030 |
Why?
|
False Positive Reactions | 2 | 2007 | 981 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 15525 | 0.030 |
Why?
|
Diastole | 1 | 2017 | 791 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7179 | 0.030 |
Why?
|
Body Weight | 2 | 2024 | 4666 | 0.030 |
Why?
|
Carbon Monoxide | 1 | 2017 | 531 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1147 | 0.030 |
Why?
|
RNA, Viral | 1 | 2023 | 2902 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2023 | 2133 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 2017 | 643 | 0.030 |
Why?
|
Stem Cells | 2 | 2021 | 3567 | 0.030 |
Why?
|
Aerospace Medicine | 1 | 1994 | 84 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1147 | 0.030 |
Why?
|
Morbidity | 1 | 2019 | 1769 | 0.030 |
Why?
|
Galectins | 1 | 2016 | 268 | 0.030 |
Why?
|
Alcoholic Intoxication | 1 | 1994 | 188 | 0.030 |
Why?
|
Antimalarials | 1 | 2020 | 907 | 0.030 |
Why?
|
Intraoperative Complications | 2 | 2012 | 1195 | 0.030 |
Why?
|
Informed Consent | 1 | 2019 | 995 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2020 | 2110 | 0.030 |
Why?
|
Oximetry | 1 | 2016 | 469 | 0.030 |
Why?
|
Pregnancy | 3 | 2012 | 29142 | 0.030 |
Why?
|
Brugada Syndrome | 1 | 2014 | 97 | 0.030 |
Why?
|
Gingival Pocket | 1 | 1992 | 7 | 0.030 |
Why?
|
Forecasting | 1 | 2022 | 2949 | 0.030 |
Why?
|
Gingival Hemorrhage | 1 | 1992 | 48 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2002 | 5076 | 0.030 |
Why?
|
Information Dissemination | 1 | 2020 | 1100 | 0.030 |
Why?
|
Dental Plaque Index | 1 | 1992 | 94 | 0.030 |
Why?
|
Periodontal Index | 1 | 1992 | 146 | 0.030 |
Why?
|
Cell Movement | 1 | 2004 | 5216 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2010 | 3509 | 0.030 |
Why?
|
Quality Assurance, Health Care | 2 | 2012 | 2211 | 0.030 |
Why?
|
Respiration | 1 | 2018 | 1651 | 0.030 |
Why?
|
Anterior Cruciate Ligament | 1 | 1995 | 415 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2017 | 2032 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2017 | 555 | 0.020 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 115 | 0.020 |
Why?
|
Toe Phalanges | 1 | 2011 | 8 | 0.020 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2012 | 194 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 2014 | 927 | 0.020 |
Why?
|
Blood Proteins | 1 | 2016 | 1123 | 0.020 |
Why?
|
Factitious Disorders | 1 | 2011 | 41 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2022 | 1432 | 0.020 |
Why?
|
Interleukin-11 | 1 | 2010 | 62 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2021 | 5974 | 0.020 |
Why?
|
Diclofenac | 1 | 2011 | 71 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 1992 | 301 | 0.020 |
Why?
|
Aging | 1 | 1990 | 8661 | 0.020 |
Why?
|
Skin Care | 1 | 2010 | 49 | 0.020 |
Why?
|
Family Health | 1 | 1996 | 1282 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2011 | 224 | 0.020 |
Why?
|
Smad3 Protein | 1 | 2010 | 180 | 0.020 |
Why?
|
Radio | 1 | 1990 | 9 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2023 | 3820 | 0.020 |
Why?
|
Growth Hormone | 1 | 1993 | 703 | 0.020 |
Why?
|
Exudates and Transudates | 1 | 2010 | 171 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 25043 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
Dyspnea | 2 | 2008 | 1303 | 0.020 |
Why?
|
Ultrasonic Therapy | 1 | 1992 | 235 | 0.020 |
Why?
|
Bayes Theorem | 2 | 2008 | 2309 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2000 | 2848 | 0.020 |
Why?
|
Fever | 1 | 2017 | 1614 | 0.020 |
Why?
|
Cardiac Imaging Techniques | 1 | 2012 | 269 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2453 | 0.020 |
Why?
|
Sodium Chloride | 1 | 1992 | 625 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14556 | 0.020 |
Why?
|
Biotransformation | 1 | 2009 | 169 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2012 | 20123 | 0.020 |
Why?
|
Self-Assessment | 1 | 1991 | 390 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1781 | 0.020 |
Why?
|
Ambulatory Care | 2 | 2011 | 2708 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 941 | 0.020 |
Why?
|
Graft Occlusion, Vascular | 1 | 2012 | 549 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.020 |
Why?
|
Fibrinolysis | 1 | 2010 | 322 | 0.020 |
Why?
|
Medical Assistance | 1 | 2009 | 104 | 0.020 |
Why?
|
Sulfones | 1 | 2011 | 437 | 0.020 |
Why?
|
Single-Blind Method | 1 | 1992 | 1590 | 0.020 |
Why?
|
Partial Thromboplastin Time | 1 | 2009 | 206 | 0.020 |
Why?
|
Joint Instability | 1 | 1996 | 792 | 0.020 |
Why?
|
Renin | 1 | 2010 | 642 | 0.020 |
Why?
|
Smoking | 2 | 2002 | 8986 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2011 | 1525 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 3703 | 0.020 |
Why?
|
Pregnancy, Animal | 1 | 1988 | 134 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9438 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 2987 | 0.020 |
Why?
|
Reading | 1 | 1991 | 558 | 0.020 |
Why?
|
Hematocrit | 1 | 2009 | 636 | 0.020 |
Why?
|
Thyroidectomy | 1 | 1993 | 879 | 0.020 |
Why?
|
Foot | 1 | 2011 | 528 | 0.020 |
Why?
|
Perfusion | 1 | 2011 | 1359 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1184 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2012 | 1206 | 0.020 |
Why?
|
Multiple Sclerosis | 1 | 2001 | 3079 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 2013 | 1082 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2011 | 6172 | 0.020 |
Why?
|
Foreign Bodies | 1 | 2011 | 399 | 0.020 |
Why?
|
Knee Joint | 1 | 1995 | 1680 | 0.020 |
Why?
|
Drug Design | 1 | 2012 | 1078 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2007 | 587 | 0.020 |
Why?
|
Thyroid Gland | 1 | 1993 | 1172 | 0.020 |
Why?
|
Spleen | 1 | 2012 | 2361 | 0.020 |
Why?
|
Life Style | 1 | 2017 | 3835 | 0.020 |
Why?
|
Antithrombin III | 1 | 2006 | 128 | 0.020 |
Why?
|
Prothrombin | 1 | 2006 | 185 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 40992 | 0.020 |
Why?
|
Leg | 1 | 2011 | 1117 | 0.020 |
Why?
|
Lactation | 1 | 1988 | 412 | 0.020 |
Why?
|
Safety | 1 | 2010 | 1185 | 0.020 |
Why?
|
Angiogenic Proteins | 1 | 2006 | 104 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4752 | 0.020 |
Why?
|
Citric Acid | 1 | 2005 | 126 | 0.020 |
Why?
|
Chemokine CCL5 | 1 | 2006 | 209 | 0.020 |
Why?
|
Hemangioendothelioma | 1 | 1986 | 121 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2010 | 681 | 0.020 |
Why?
|
Selenium | 1 | 1988 | 405 | 0.020 |
Why?
|
Fetus | 1 | 1993 | 1880 | 0.020 |
Why?
|
Cross Reactions | 1 | 2007 | 841 | 0.020 |
Why?
|
Mental Recall | 1 | 1991 | 1205 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2007 | 405 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2007 | 1095 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2010 | 921 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2009 | 436 | 0.020 |
Why?
|
Monensin | 1 | 2004 | 29 | 0.020 |
Why?
|
Brefeldin A | 1 | 2004 | 72 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 12742 | 0.020 |
Why?
|
Homozygote | 1 | 2009 | 1786 | 0.020 |
Why?
|
Hydroxytestosterones | 1 | 2004 | 3 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 276 | 0.020 |
Why?
|
Enzymes | 1 | 2006 | 266 | 0.020 |
Why?
|
Child | 3 | 2022 | 77679 | 0.020 |
Why?
|
Electrophysiology | 1 | 2007 | 1310 | 0.020 |
Why?
|
Insurance Claim Review | 1 | 2009 | 720 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2011 | 1404 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9311 | 0.010 |
Why?
|
Attitude of Health Personnel | 2 | 2010 | 3842 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2010 | 1404 | 0.010 |
Why?
|
Vitamin E | 1 | 1988 | 869 | 0.010 |
Why?
|
Life Tables | 1 | 2004 | 370 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3588 | 0.010 |
Why?
|
Calcium | 2 | 2009 | 5757 | 0.010 |
Why?
|
Solubility | 1 | 2005 | 1083 | 0.010 |
Why?
|
Growth Substances | 1 | 2006 | 783 | 0.010 |
Why?
|
Tritium | 1 | 2004 | 746 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5180 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2009 | 1682 | 0.010 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2004 | 361 | 0.010 |
Why?
|
Fees, Pharmaceutical | 1 | 2002 | 64 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2781 | 0.010 |
Why?
|
Heterozygote | 1 | 2009 | 2805 | 0.010 |
Why?
|
Drug Interactions | 1 | 2007 | 1458 | 0.010 |
Why?
|
Genome-Wide Association Study | 2 | 2012 | 12264 | 0.010 |
Why?
|
Alleles | 1 | 2013 | 6938 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 1574 | 0.010 |
Why?
|
Memory | 1 | 1991 | 2174 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1485 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2004 | 628 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 2007 | 783 | 0.010 |
Why?
|
Attitude to Health | 1 | 2010 | 2053 | 0.010 |
Why?
|
Weight Gain | 1 | 2011 | 2292 | 0.010 |
Why?
|
Time | 1 | 2003 | 541 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6274 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5881 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2005 | 1423 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2009 | 1888 | 0.010 |
Why?
|
Pain Measurement | 1 | 2010 | 3419 | 0.010 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2006 | 859 | 0.010 |
Why?
|
Lactic Acid | 1 | 2005 | 1132 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2004 | 2030 | 0.010 |
Why?
|
Testis | 1 | 2004 | 800 | 0.010 |
Why?
|
Health Policy | 1 | 2012 | 2661 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 7022 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2004 | 1801 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3385 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2006 | 1602 | 0.010 |
Why?
|
Diet | 1 | 2017 | 7937 | 0.010 |
Why?
|
Sequence Tagged Sites | 1 | 1999 | 94 | 0.010 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 118 | 0.010 |
Why?
|
Ovary | 1 | 2004 | 981 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2011 | 1947 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2004 | 1240 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 3474 | 0.010 |
Why?
|
Arm | 1 | 2001 | 590 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2006 | 1161 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2011 | 11368 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 12956 | 0.010 |
Why?
|
Lymphoma | 1 | 1986 | 1873 | 0.010 |
Why?
|
Pericardium | 1 | 2001 | 667 | 0.010 |
Why?
|
Triglycerides | 1 | 2004 | 2453 | 0.010 |
Why?
|
Macrophages | 1 | 2011 | 5657 | 0.010 |
Why?
|
Estradiol | 1 | 2004 | 2020 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2010 | 35423 | 0.010 |
Why?
|
Primary Health Care | 1 | 2012 | 4556 | 0.010 |
Why?
|
Kinetics | 1 | 2004 | 6474 | 0.010 |
Why?
|
Electric Stimulation Therapy | 1 | 2001 | 605 | 0.010 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 1875 | 0.010 |
Why?
|
Calcinosis | 1 | 2004 | 1499 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2886 | 0.010 |
Why?
|
Anemia | 1 | 2005 | 1504 | 0.010 |
Why?
|
Pain | 1 | 2010 | 4987 | 0.010 |
Why?
|
HIV Infections | 1 | 2021 | 16718 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2004 | 1939 | 0.010 |
Why?
|
Placenta | 1 | 2004 | 1697 | 0.010 |
Why?
|
DNA Primers | 1 | 1999 | 2892 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2001 | 1828 | 0.010 |
Why?
|
Lung Diseases | 1 | 2004 | 1885 | 0.010 |
Why?
|
Cognition | 1 | 1991 | 6765 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 1999 | 1586 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2004 | 2916 | 0.010 |
Why?
|
Biomedical Engineering | 1 | 1995 | 296 | 0.010 |
Why?
|
Swine | 1 | 2004 | 5940 | 0.010 |
Why?
|
Physicians | 1 | 1991 | 4564 | 0.010 |
Why?
|
Testosterone | 1 | 2004 | 2411 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 25618 | 0.010 |
Why?
|
Weight-Bearing | 1 | 1995 | 515 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1993 | 918 | 0.010 |
Why?
|
Autoradiography | 1 | 1993 | 749 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1993 | 1581 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 4935 | 0.010 |
Why?
|
Sheep | 1 | 1993 | 1437 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17449 | 0.010 |
Why?
|
Thyroxine | 1 | 1993 | 666 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9582 | 0.000 |
Why?
|
Base Sequence | 1 | 1999 | 12801 | 0.000 |
Why?
|
Frozen Sections | 1 | 1986 | 155 | 0.000 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1993 | 2014 | 0.000 |
Why?
|
Gestational Age | 1 | 1993 | 3493 | 0.000 |
Why?
|
Postoperative Complications | 1 | 2006 | 15294 | 0.000 |
Why?
|
Blood Vessels | 1 | 1986 | 1126 | 0.000 |
Why?
|
Frontal Lobe | 1 | 1986 | 1407 | 0.000 |
Why?
|
Antigens, Neoplasm | 1 | 1986 | 1987 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 1986 | 4665 | 0.000 |
Why?
|
Skin | 1 | 1986 | 4363 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1986 | 10182 | 0.000 |
Why?
|